#12: Migraine as a Progressive Disorder
February 27th, 2008
Headway Episode #12: Migraine as a Progressive Disorder
Interview with: Stephen D. Silberstein, MD, FACP
Disclosure: Dr. Silberstein has received grants from Abbott, Advanced Bionics, Advanced Neuro-Modulation System, AGA, Lilly, ProEthic and Vernalis. He has received grants and honorarium from Allergan, AstraZeneca, Endo Pharmaceuticals, GlaxoSmithKline, Medtronic, Merck, Ortho-McNeil, Pfizer, Pozen and Valeant Pharmaceuticals.
News Topper References:
1. Rodés-Cabau J, Mineau S, Marrero A, et al. Incidence, timing and predictive factors of new-onset migraine headache occurrence after transcatheter closure of atrial septal defects or patent foramen ovale. Abstract presented at: European Society of Cardiology Annual Congress; Sept 1-5, 2007; Vienna, Austria. Abstract #4258.
2. Marrero A, Rodés-Cabau J, Mineau S, Marrero, et al. Incidence, timing and predictive factors of new-onset migraine headache occurrence after transcatheter closure of atrial septal defects or patent foramen ovale. Slides presented at: European Society of Cardiology Annual Congress; Sept 1-5, 2007; Vienna, Austria; Slides available at: http://spo.escardio.org/eslides/presenter.aspx?eevtid=19&letter=M. Accessed December 11, 2007.
3. Jancin, B. Cardiac procedure linked to new-onset migraine. Clinical Neurology News. 2007;3(10):1, 6.
4. Beda RD, Gill EA Jr. Patent foramen ovale: Does it play a role in the pathophysiology of migraine headache? Cardiol Clin. 2005;23:91–96.
5. Giardini A, Donti A, Formigari R, et al. Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. Am Heart J. 2006;922:e1-922.e5.
6. Slavin L, Tobis JM, Rangarajan K, Dao C, Krivokapich J, Liebeskind DS. Five-year experience with percutaneous closure of patent foramen ovale. Am J Cardiol. 2007;99:1316-1320.
7. Valente AM, Rhodes JF. Current indications and contraindications for transcatheter atrial septal defect and patent foramen ovale device closure. Am Heart J. 2007;153(4 Suppl):81-84.
Interview References:
1. Loder E, Biondi D. Disease modification in migraine: A concept that has come of age? Headache. 2003;43:135-143.
2. Bigal, ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Chronic migraine is an earlier stage of transformed migraine in adults. Neurology. 2005;65:1556-1561.
3. Lipton RB, Pan J. Is migraine a progressive brain disease? JAMA. 2004;291:493-494.
4. Schreiber CP. The pathophysiology of migraine. Clin Fam Pract. 2005;7:407-421.
5. Silberstein SD, Lipton RB, Ramadan NM. From migraine mechanisms to innovative
therapeutic drugs. Neurology. 2005;64(suppl 2):S1-S3.
6. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and
cutaneous allodynia. Ann Neurol. 2000;47:614–24.
7. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race
against the development of cutaneous allodynia. Ann Neurol. 2004;55:19–26.
8. Smith TR. The pharmacologic treatment of the acute migraine attack. Clin Fam Pract. 2005;7:423-444.
9. Bousser M-G, Welch MA. Relation between migraine and stroke. Lancet Neurol. 2005; 4:533–542.
10. Milhaud D, Bogousslavsky J, van Melle G, Liot P. Ischemic stroke and active migraine. Neurology. 2001;57:1805-1811.
11. Bushnell CD. Oestrogen and stroke in women: Assessment of risk. Lancet Neurol. 2005;4:743–751.
12. Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of
stroke in women: A prospective study. Neurology. 2005;64:1020–1026.
13. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies. BMJ. 2005;330: 63.
14. Armstrong C. ACOG releases guidelines on hormonal contraceptives in women with coexisting medical conditions. Am Fam Physician. 2007;75;1252-1258.
15. Tepper SJ, Dahlof CGH, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: Data from the Landmark Study. Headache. 2004;44:856-864.
